Show simple item record

dc.contributor.authorAngerilli, V
dc.contributor.authorFontana, E
dc.contributor.authorLonardi, S
dc.contributor.authorSbaraglia, M
dc.contributor.authorBorelli, B
dc.contributor.authorMunari, G
dc.contributor.authorSalmaso, R
dc.contributor.authorGuzzardo, V
dc.contributor.authorSpolverato, G
dc.contributor.authorPucciarelli, S
dc.contributor.authorPilati, P
dc.contributor.authorHahne, JC
dc.contributor.authorBergamo, F
dc.contributor.authorZagonel, V
dc.contributor.authorDei Tos, AP
dc.contributor.authorSadanandam, A
dc.contributor.authorLoupakis, F
dc.contributor.authorValeri, N
dc.contributor.authorFassan, M
dc.date.accessioned2021-09-28T08:32:34Z
dc.date.available2021-09-28T08:32:34Z
dc.identifier.citationESMO open, 2021, 6 (4), pp. 100211 - ?
dc.identifier.issn2059-7029
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4830
dc.identifier.eissn2059-7029
dc.identifier.doi10.1016/j.esmoop.2021.100211
dc.description.abstractBackground Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity provides the fuel for drug resistance; therefore, an accurate assessment of tumor heterogeneity is essential for the development of effective therapies. The purpose of this study was to dissect morphologic and molecular ITH in colorectal adenocarcinoma.Materials and methods A series of 120 V600E BRAF-mutated ( V600E BRAFmt) consecutive metastatic colorectal adenocarcinomas was assessed for morphologic heterogeneity. The two heterogeneous components of each specimen underwent a histopathological, immunohistochemical and molecular characterization to evaluate: histologic variant, grading, tumor-infiltrating lymphocytes (TILs), mismatch repair proteins' expression, KRAS/BRAF/NRAS mutations, microsatellite instability (MSI) status and consensus molecular subtype (CMS).Results Thirty-one out of 120 (25.8%) V600E BRAFmt primary colorectal adenocarcinomas presented a heterogeneous morphology. Among these, eight cases had adequate material for molecular profiling. Five out of the eight (62.5%) cases resulted instable at MSI testing. The majority (62.5%) of the samples showed a CMS4 phenotype based on gene expression profiling. Heterogeneity in CMS classification was observed in four out of eight cases. One out of eight cases presented significant heterogeneity in the number of TILs between the two components of the tumor.Conclusions Although the distribution of the immune infiltrate appears relatively conserved among heterogeneous areas of the same tumor, changes in gene expression profile and CMS occur in 50% of V600E BRAFmt adenocarcinoma cases in our small series and might contribute to variability in response to anticancer therapy and clinical outcomes. Assessment of morphological and molecular ITH is needed to improve colorectal cancer classification and to tailor anticancer treatments and should be included in the pathology report.
dc.formatPrint-Electronic
dc.format.extent100211 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleIntratumor morphologic and transcriptomic heterogeneity in <sup>V600E</sup>BRAF-mutated metastatic colorectal adenocarcinomas.
dc.typeJournal Article
dcterms.dateAccepted2021-06-25
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.esmoop.2021.100211
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfESMO open
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Systems and Precision Cancer Medicine
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Systems and Precision Cancer Medicine
pubs.publication-statusPublished
pubs.volume6
pubs.embargo.termsNot known
icr.researchteamGastrointestinal Cancer Biology and Genomics
icr.researchteamSystems and Precision Cancer Medicine
icr.researchteamGastrointestinal Cancer Biology and Genomicsen_US
icr.researchteamSystems and Precision Cancer Medicineen_US
dc.contributor.icrauthorHahne, Jensen
dc.contributor.icrauthorSadanandam, Angurajen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0